CN110291085B - 突变型异柠檬酸脱氢酶抑制剂、组合物及其方法 - Google Patents

突变型异柠檬酸脱氢酶抑制剂、组合物及其方法 Download PDF

Info

Publication number
CN110291085B
CN110291085B CN201780086231.0A CN201780086231A CN110291085B CN 110291085 B CN110291085 B CN 110291085B CN 201780086231 A CN201780086231 A CN 201780086231A CN 110291085 B CN110291085 B CN 110291085B
Authority
CN
China
Prior art keywords
amino
ethyl
pyrimidin
isopropyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780086231.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110291085A (zh
Inventor
张廷虎
车健为
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aike Biotechnology Co ltd
Original Assignee
Aike Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aike Biotechnology Co ltd filed Critical Aike Biotechnology Co ltd
Publication of CN110291085A publication Critical patent/CN110291085A/zh
Application granted granted Critical
Publication of CN110291085B publication Critical patent/CN110291085B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201780086231.0A 2016-12-19 2017-12-18 突变型异柠檬酸脱氢酶抑制剂、组合物及其方法 Expired - Fee Related CN110291085B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662436328P 2016-12-19 2016-12-19
US62/436,328 2016-12-19
US201762536367P 2017-07-24 2017-07-24
US62/536,367 2017-07-24
PCT/US2017/067050 WO2018118793A1 (en) 2016-12-19 2017-12-18 Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof

Publications (2)

Publication Number Publication Date
CN110291085A CN110291085A (zh) 2019-09-27
CN110291085B true CN110291085B (zh) 2023-01-24

Family

ID=62627122

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780086231.0A Expired - Fee Related CN110291085B (zh) 2016-12-19 2017-12-18 突变型异柠檬酸脱氢酶抑制剂、组合物及其方法

Country Status (8)

Country Link
US (2) US11149032B2 (OSRAM)
EP (1) EP3555079A4 (OSRAM)
JP (1) JP2020502116A (OSRAM)
KR (1) KR20190092476A (OSRAM)
CN (1) CN110291085B (OSRAM)
AU (1) AU2017379796B2 (OSRAM)
CA (1) CA3047136A1 (OSRAM)
WO (1) WO2018118793A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311863B (zh) * 2016-06-06 2021-10-29 伊莱利利公司 突变型idh1抑制剂
WO2019213403A1 (en) 2018-05-02 2019-11-07 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
AU2019291935A1 (en) * 2018-06-29 2021-02-04 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
CN111825666B (zh) * 2019-04-23 2024-03-08 上海仕谱生物科技有限公司 二聚或多聚体形式的突变型idh抑制剂
WO2022056453A1 (en) * 2020-09-14 2022-03-17 Totus Medicines Inc. Therapeutic conjugates
CN120554346A (zh) * 2024-02-28 2025-08-29 中国科学院上海药物研究所 一类噁唑酮取代的嘧啶胺化合物及其制备方法、药物组合物和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958506A (zh) * 2011-09-27 2014-07-30 诺华股份有限公司 用作突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030004174A9 (en) * 2000-02-17 2003-01-02 Armistead David M. Kinase inhibitors
WO2008080937A1 (en) * 2006-12-28 2008-07-10 Basf Se 2-substituted pyrimidines i in therapy
CA2961793C (en) * 2014-09-19 2021-03-16 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
WO2017140758A1 (en) * 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
CN109311863B (zh) * 2016-06-06 2021-10-29 伊莱利利公司 突变型idh1抑制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958506A (zh) * 2011-09-27 2014-07-30 诺华股份有限公司 用作突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Levell, Julian R. et al..Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1.《ACS Medicinal Chemistry Letters 》.2016, *
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1;Levell, Julian R. et al.;《ACS Medicinal Chemistry Letters 》;20161206;第151-156页 *

Also Published As

Publication number Publication date
AU2017379796B2 (en) 2021-10-21
WO2018118793A1 (en) 2018-06-28
EP3555079A4 (en) 2020-08-19
US11149032B2 (en) 2021-10-19
US20210403460A1 (en) 2021-12-30
AU2017379796A1 (en) 2019-07-04
US20200071309A1 (en) 2020-03-05
CA3047136A1 (en) 2018-06-28
CN110291085A (zh) 2019-09-27
JP2020502116A (ja) 2020-01-23
EP3555079A1 (en) 2019-10-23
KR20190092476A (ko) 2019-08-07

Similar Documents

Publication Publication Date Title
CN110291085B (zh) 突变型异柠檬酸脱氢酶抑制剂、组合物及其方法
RU2727198C2 (ru) Производное бензофурана, способ его получения и его применение в медицине
CN118510778A (zh) 作为DNA聚合酶θ抑制剂的噻唑并吡啶基酰胺衍生物
KR102607934B1 (ko) 바닌 억제제로서의 헤테로방향족 화합물
WO2014134774A1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2018010514A1 (zh) 作为fgfr抑制剂的杂环化合物
JP2024505732A (ja) ピリドピリミジノン系誘導体及びその製造方法と使用
CN105884695B (zh) 杂环衍生物类酪氨酸激酶抑制剂
CN111051309A (zh) 可用作a2a受体拮抗剂的三唑并三嗪衍生物
WO2020215998A1 (zh) 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
KR102649802B1 (ko) 피리미딘 유도체
US20210101899A1 (en) Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof
WO2022174765A1 (zh) 作为Wee-1抑制剂的稠环化合物
CN111278827B (zh) 突变型异柠檬酸脱氢酶抑制剂、组合物及其方法
TWI890929B (zh) 作為Wee-1抑制劑的嘧啶化合物
HK40082792A (en) Compound for targeting and degrading protein, and preparation method therefor and use thereof
HK40019786A (en) Triazolotriazine derivatives as a2a receptor antagonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20230124

CF01 Termination of patent right due to non-payment of annual fee